Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2...

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Vascular endothelial growth factor (VEGF) drives tumor angiogenesis by activating VEGF receptor (VEGFR) tyrosine kinases.
• A soluble form of VEGFR-2 (sVEGFR-2) is detectable in plasma and of clinical interest as a biomarker.
• Preclinical data on sVEGFR-2 modulation during tumor growth and its underlying mechanisms were lacking.

Purpose of the Study:

• To investigate the relationship between plasma sVEGFR-2 levels and tumor burden in vivo.
• To elucidate the mechanisms regulating sVEGFR-2 levels during tumor growth.
• To assess the role of tumor-derived VEGF in modulating sVEGFR-2.

Main Methods:

• Utilized spontaneously growing tumors and human tumor xenografts (localized and metastatic).
• Employed VEGF overexpression models (cell transfection, adenoviral delivery) in vivo.
• Conducted in vitro studies to investigate VEGF-mediated VEGFR-2 modulation.

Main Results:

• Observed an inverse correlation between plasma sVEGFR-2 levels and tumor size.
• Demonstrated that tumor-derived VEGF significantly reduces plasma sVEGFR-2 levels.
• Showed in vitro that VEGF induces VEGFR-2 down-regulation from the cell surface.

Conclusions:

• Plasma sVEGFR-2 levels are inversely related to tumor burden.
• Tumor-derived VEGF plays a critical role in decreasing sVEGFR-2 levels via receptor down-regulation.
• Findings support the clinical utility of sVEGFR-2 as a biomarker for VEGF-dependent tumor growth and antiangiogenic therapy efficacy.